Practice

Investigators Study Risks of Hypertension, Proteinuria With Bevacizumab

January 19, 2021

Tony Hagen

Article

The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.

Swift Uptake for Mvasi Suggests Provider Comfort With Use

January 18, 2021

Tony Hagen

Article

Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.

Infliximab Biosimilar Switching Study Yields Evidence of Safety, Efficacy

January 14, 2021

Deana Ferreri, PhD

Article

A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.

A Review of the Most-Read Biosimilar Stories of 2020: Part 2

December 27, 2020

Tony Hagen

Article

In part 2 of this year-end feature, we look at the most-read biosimilar stories of the second half of 2020.

A Review of the Most-Read Biosimilar Stories in 2020: Part 1

December 24, 2020

Tony Hagen

Article

The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.

Samsung Bioepis Examines European Awareness of Biosimilars

December 19, 2020

Tony Hagen

Article

In the EU-5 group of countries, biosimilar awareness is poor, hindering uptake of these potentially cost-saving medicines, a white paper states.

Samsung Bioepis Initiates Phase 3 Trial for Denosumab Biosimilar

December 16, 2020

Tony Hagen

Article

Samsung Bioepis hopes to gain regulatory approval for a denosumab biosimilar referencing Prolia. The trial will focus on women with postmenopausal osteoporosis.

Trastuzumab Biosimilar With PIK3CA Inhibitor Shows Efficacy in Advanced Breast Cancer

December 10, 2020

Tony Hagen

Article

Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.

Romiplostim Biosimilar Study Demonstrates Safety, Efficacy in Real-World India Population

December 8, 2020

Tony Hagen

Article

A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.

Investigators: Biosimilar Pegfilgrastim Has Advantages Over Wearable Injector

December 1, 2020

Tony Hagen

Article

The wearable injector has a failure rate that adds hospitalization costs; therefore, biosimilar pegfilgrastim may hold cost advantages, investigators conclude.

x